Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging

Eric M. Reiman, Kewei Chen, Jessica B S Langbaum, Wendy Lee, Cole Reschke, Daniel Bandy, Gene E. Alexander, Richard John Caselli

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Epidemiological studies suggest that higher midlife serum total cholesterol levels are associated with an increased risk of Alzheimer's disease (AD). Using fluorodeoxyglucose positron emission tomography (PET) in the study of cognitively normal late middle-aged people, we demonstrated an association between apolipoprotein E (APOE) e{open}4 gene dose, the major genetic risk factor for late-onset AD, and lower measurements of the cerebral metabolic rate for glucose (CMRgl) in AD-affected brain regions, we proposed using PET as a pre-symptomatic endophenotype to evaluate other putative AD risk modifiers, and we then used it to support an aggregate cholesterol-related genetic risk score in the risk of AD. In the present study, we used PET to investigate the association between serum total cholesterol levels and cerebral metabolic rate for glucose metabolism (CMRgl) in 117 cognitively normal late middle-aged APOE e{open}4 homozygotes, heterozygotes and non-carriers. Higher serum total cholesterol levels were associated with lower CMRgl bilaterally in precuneus, parietotemporal and prefrontal regions previously found to be preferentially affected by AD, and in additional frontal regions previously found to be preferentially affected by normal aging. The associations were greater in APOE e{open}4 carriers than non-carriers in some of the AD-affected brain regions. We postulate that higher midlife serum total cholesterol levels accelerate brain processes associated with normal aging and conspire with other risk factors in the predisposition to AD. We propose using PET in proof-of-concept randomized controlled trials to rapidly evaluate the effects of midlife cholesterol-lowering treatments on the brain changes associated with normal aging and AD.

Original languageEnglish (US)
Pages (from-to)169-176
Number of pages8
JournalNeuroImage
Volume49
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Alzheimer Disease
Cholesterol
Glucose
Brain
Serum
Positron-Emission Tomography
Apolipoproteins E
Endophenotypes
Parietal Lobe
Homozygote
Heterozygote
Epidemiologic Studies
Randomized Controlled Trials
Genes

Keywords

  • Aging
  • Alzheimer's disease
  • Cholesterol
  • Positron emission tomography

ASJC Scopus subject areas

  • Cognitive Neuroscience
  • Neurology

Cite this

Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging. / Reiman, Eric M.; Chen, Kewei; Langbaum, Jessica B S; Lee, Wendy; Reschke, Cole; Bandy, Daniel; Alexander, Gene E.; Caselli, Richard John.

In: NeuroImage, Vol. 49, No. 1, 01.01.2010, p. 169-176.

Research output: Contribution to journalArticle

Reiman, Eric M. ; Chen, Kewei ; Langbaum, Jessica B S ; Lee, Wendy ; Reschke, Cole ; Bandy, Daniel ; Alexander, Gene E. ; Caselli, Richard John. / Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging. In: NeuroImage. 2010 ; Vol. 49, No. 1. pp. 169-176.
@article{bc047914c9ca4c22ae2062fc4b469db2,
title = "Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging",
abstract = "Epidemiological studies suggest that higher midlife serum total cholesterol levels are associated with an increased risk of Alzheimer's disease (AD). Using fluorodeoxyglucose positron emission tomography (PET) in the study of cognitively normal late middle-aged people, we demonstrated an association between apolipoprotein E (APOE) e{open}4 gene dose, the major genetic risk factor for late-onset AD, and lower measurements of the cerebral metabolic rate for glucose (CMRgl) in AD-affected brain regions, we proposed using PET as a pre-symptomatic endophenotype to evaluate other putative AD risk modifiers, and we then used it to support an aggregate cholesterol-related genetic risk score in the risk of AD. In the present study, we used PET to investigate the association between serum total cholesterol levels and cerebral metabolic rate for glucose metabolism (CMRgl) in 117 cognitively normal late middle-aged APOE e{open}4 homozygotes, heterozygotes and non-carriers. Higher serum total cholesterol levels were associated with lower CMRgl bilaterally in precuneus, parietotemporal and prefrontal regions previously found to be preferentially affected by AD, and in additional frontal regions previously found to be preferentially affected by normal aging. The associations were greater in APOE e{open}4 carriers than non-carriers in some of the AD-affected brain regions. We postulate that higher midlife serum total cholesterol levels accelerate brain processes associated with normal aging and conspire with other risk factors in the predisposition to AD. We propose using PET in proof-of-concept randomized controlled trials to rapidly evaluate the effects of midlife cholesterol-lowering treatments on the brain changes associated with normal aging and AD.",
keywords = "Aging, Alzheimer's disease, Cholesterol, Positron emission tomography",
author = "Reiman, {Eric M.} and Kewei Chen and Langbaum, {Jessica B S} and Wendy Lee and Cole Reschke and Daniel Bandy and Alexander, {Gene E.} and Caselli, {Richard John}",
year = "2010",
month = "1",
day = "1",
doi = "10.1016/j.neuroimage.2009.07.025",
language = "English (US)",
volume = "49",
pages = "169--176",
journal = "NeuroImage",
issn = "1053-8119",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging

AU - Reiman, Eric M.

AU - Chen, Kewei

AU - Langbaum, Jessica B S

AU - Lee, Wendy

AU - Reschke, Cole

AU - Bandy, Daniel

AU - Alexander, Gene E.

AU - Caselli, Richard John

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Epidemiological studies suggest that higher midlife serum total cholesterol levels are associated with an increased risk of Alzheimer's disease (AD). Using fluorodeoxyglucose positron emission tomography (PET) in the study of cognitively normal late middle-aged people, we demonstrated an association between apolipoprotein E (APOE) e{open}4 gene dose, the major genetic risk factor for late-onset AD, and lower measurements of the cerebral metabolic rate for glucose (CMRgl) in AD-affected brain regions, we proposed using PET as a pre-symptomatic endophenotype to evaluate other putative AD risk modifiers, and we then used it to support an aggregate cholesterol-related genetic risk score in the risk of AD. In the present study, we used PET to investigate the association between serum total cholesterol levels and cerebral metabolic rate for glucose metabolism (CMRgl) in 117 cognitively normal late middle-aged APOE e{open}4 homozygotes, heterozygotes and non-carriers. Higher serum total cholesterol levels were associated with lower CMRgl bilaterally in precuneus, parietotemporal and prefrontal regions previously found to be preferentially affected by AD, and in additional frontal regions previously found to be preferentially affected by normal aging. The associations were greater in APOE e{open}4 carriers than non-carriers in some of the AD-affected brain regions. We postulate that higher midlife serum total cholesterol levels accelerate brain processes associated with normal aging and conspire with other risk factors in the predisposition to AD. We propose using PET in proof-of-concept randomized controlled trials to rapidly evaluate the effects of midlife cholesterol-lowering treatments on the brain changes associated with normal aging and AD.

AB - Epidemiological studies suggest that higher midlife serum total cholesterol levels are associated with an increased risk of Alzheimer's disease (AD). Using fluorodeoxyglucose positron emission tomography (PET) in the study of cognitively normal late middle-aged people, we demonstrated an association between apolipoprotein E (APOE) e{open}4 gene dose, the major genetic risk factor for late-onset AD, and lower measurements of the cerebral metabolic rate for glucose (CMRgl) in AD-affected brain regions, we proposed using PET as a pre-symptomatic endophenotype to evaluate other putative AD risk modifiers, and we then used it to support an aggregate cholesterol-related genetic risk score in the risk of AD. In the present study, we used PET to investigate the association between serum total cholesterol levels and cerebral metabolic rate for glucose metabolism (CMRgl) in 117 cognitively normal late middle-aged APOE e{open}4 homozygotes, heterozygotes and non-carriers. Higher serum total cholesterol levels were associated with lower CMRgl bilaterally in precuneus, parietotemporal and prefrontal regions previously found to be preferentially affected by AD, and in additional frontal regions previously found to be preferentially affected by normal aging. The associations were greater in APOE e{open}4 carriers than non-carriers in some of the AD-affected brain regions. We postulate that higher midlife serum total cholesterol levels accelerate brain processes associated with normal aging and conspire with other risk factors in the predisposition to AD. We propose using PET in proof-of-concept randomized controlled trials to rapidly evaluate the effects of midlife cholesterol-lowering treatments on the brain changes associated with normal aging and AD.

KW - Aging

KW - Alzheimer's disease

KW - Cholesterol

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=70349987633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349987633&partnerID=8YFLogxK

U2 - 10.1016/j.neuroimage.2009.07.025

DO - 10.1016/j.neuroimage.2009.07.025

M3 - Article

C2 - 19631758

AN - SCOPUS:70349987633

VL - 49

SP - 169

EP - 176

JO - NeuroImage

JF - NeuroImage

SN - 1053-8119

IS - 1

ER -